Unknown

Dataset Information

0

Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos.


ABSTRACT:

Background

Carbon nanotubes have shown broad potential in biomedical applications, given their unique mechanical, optical, and chemical properties. In this pilot study, carbon nanotubes have been explored as multimodal drug delivery vectors that facilitate antiangiogenic therapy in zebrafish embryos.

Methods

Three different agents, ie, an antiangiogenic binding site (cyclic arginine-glycin-easpartic acid), an antiangiogenic drug (thalidomide), and a tracking dye (rhodamine), were conjugated onto single-walled carbon nanotubes (SWCNT). The biodistribution, efficacy, and biocompatibility of these triple functionalized SWCNT were tested in mammalian cells and validated in transparent zebrafish embryos.

Results

Accumulation of SWCNT-associated nanoconjugates in blastoderm cells facilitated drug delivery applications. Mammalian cell xenograft assays demonstrated that these antiangiogenic SWCNT nanoconjugates specifically inhibited ectopic angiogenesis in the engrafted zebrafish embryos.

Conclusion

This study highlights the potential of using SWCNT for generating efficient nanotherapeutics.

SUBMITTER: Cheng J 

PROVIDER: S-EPMC3181060 | biostudies-literature | 2011

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos.

Cheng Jinping J   Gu Yan-Juan YJ   Wang Yajun Y   Cheng Shuk Han SH   Wong Wing-Tak WT  

International journal of nanomedicine 20110915


<h4>Background</h4>Carbon nanotubes have shown broad potential in biomedical applications, given their unique mechanical, optical, and chemical properties. In this pilot study, carbon nanotubes have been explored as multimodal drug delivery vectors that facilitate antiangiogenic therapy in zebrafish embryos.<h4>Methods</h4>Three different agents, ie, an antiangiogenic binding site (cyclic arginine-glycin-easpartic acid), an antiangiogenic drug (thalidomide), and a tracking dye (rhodamine), were  ...[more]

Similar Datasets

| S-EPMC2613370 | biostudies-literature
| S-EPMC4068527 | biostudies-literature
| S-EPMC3683668 | biostudies-literature
| S-EPMC8124397 | biostudies-literature
| S-EPMC6310896 | biostudies-other
| S-EPMC4758231 | biostudies-literature
| S-EPMC10454396 | biostudies-literature
| S-EPMC6698876 | biostudies-other
| S-EPMC7710741 | biostudies-literature
| S-EPMC3041115 | biostudies-other